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Abstract:	Optic	nerve	hypoplasia	(ONH)	is	the	most	common	congenital	optic	nerve	anomaly	and	a	leading	cause	of	blindness	in	the	USA.	Although	most	cases	of	ONH	occur	as	isolated	cases	within	their	respective	families,	the	advancement	in	molecular	diagnostic	technology	has	made	us	realise	that	a	substantial	fraction	of	cases	has	identifiable	genetic	causes,	typically	de	novo	mutations.	An	increasing	number	of	genes	has	been	reported,	mutations	of	which	can	cause	ONH.	Many	of	the	genes	involved	serve	as	transcription	factors,	participating	in	an	intricate	multistep	process	critical	to	eye	development	and	neurogenesis	in	the	neural	retina.	This	review	will	discuss	the	respective	genes	and	mutations,	human	phenotypes,	and	animal	models	that	have	been	created	to	gain	a	deeper	understanding	of	the	disorders.	The	identification	of	the	underlying	gene	and	mutation	provides	an	important	step	in	diagnosis,	medical	care	and	counselling	for	the	affected	individuals	and	their	families.	We	envision	that	future	research	will	lead	to	further	disease	gene	identification,	but	will	also	teach	us	about	gene–gene	and	gene–environment	interactions	relevant	to	optic	nerve	development.	How	much	of	the	functional	impairment	of	the	various	forms	of	ONH	is	a	reflection	of	altered	morphogenesis	versus	neuronal	homeostasis	will	determine	the	prospect	of	therapeutic	intervention,	with	the	ultimate	goal	of	improving	the	quality	of	life	of	the	individuals	affected	with	ONH.			
Introduction:		The	optic	nerve,	which	is	composed	of	retinal	ganglion	cell	axons	and	supporting	glial	cells,	transmits	visual	information	from	the	retina	to	the	brain.	Optic	nerve	hypoplasia	(ONH)	is	a	non-progressive	congenital	abnormality	characterized	by	underdevelopment	of	the	optic	nerve.	Typically,	the	anomalous	optic	nerve	head	appears	pale	and	small,	with	a	pale	or	pigmented	peripapillary	halo	or	double-ringed	sign	that	is	visible	with	ophthalmoscopy.	ONH	may	occur	bilaterally	(in	both	eyes)	or	unilaterally	(in	one	eye),	although	it	is	more	commonly	bilaterally	(80%).	Individuals	with	ONH	manifest	different	levels	of	visual	impairment,	which	spans	a	wide	range.	Some	eyes	with	ONH	have	no	light	perception,	while	others	have	acceptable	levels	of	functional	vision.	Severe	bilateral	ONH	can	be	diagnosed	within	the	first	few	months	of	life.	Affected	patients	typically	manifest	early-onset	sensory	nystagmus	(involuntary,	rapid	eye	movements),	followed	by	strabismus	(inability	to	
align	the	eyes	simultaneously)	often	related	to	the	visual	impairment	due	to	defective	communication	between	eye	and	brain.	Individuals	with	unilateral	ONH	are	often	diagnosed	at	an	older	age,	compared	to	those	with	bilateral	ONH,	due	to	preserved	vision	in	the	one	normal	eye.		The	first	recorded	case	of	ONH	was	documented	in	1884	in	a	small	child	by	Magnus1.		Magnus	noticed	a	small,	pale	optic	nerve	in	a	boy	with	nystagmus	and	a	high	degree	of	amblyopia.	However,	some	researchers	considered	Briere’s	report	to	be	the	first	case	in	18772.	He	described	a	7-year-old	girl	who	was	born	blind,	with	no	observed	or	documented	optic	disc,	but	normal	choroid	and	central	retinal	vessels.	The	first	schematic	illustration	of	optic	disc	appearance	of	ONH	was	done	by	Schwarz	in	19153.	To	date,	OHN	is	the	third	leading	cause	of	blindness	and	is	the	most	common	congenital	optic	nerve	anomaly	in	the	United	States4,5.	The	reported	prevalences	of	ONH	ranges	from	2-17.3	per	100,0006-11,	with	a	considerable	rise	in	prevalence	starting	in	the	1980s.	The	cause	of	this	increase	remains	disputed;	however,	it	may	be	due	to	heightened	physician	awareness	and	improved	observation	and	thus	diagnosis	of	the	disorder.	Given	that	most	ONH	cases	are	isolated	within	their	respective	families,	research	into	the	causal	factors	of	ONH	has	focused	on	environmental	effects.	Many	environmental	risk	factors	for	ONH	have	been	reported,	including	maternal	alcohol	abuse	during	pregnancy12,13,	young	maternal	age,	primiparity14-16,	maternal	use	of	recreational	drugs10,17,	anticonvulsants18,	or	antidepressant19,20.	However,	familial	cases	of	ONH	also	exist21,22,	suggesting	genetic	etiologies.	With	the	recent	advancement	in	molecular	diagnostic	technology,	mutations	in	an	increasing	number	of	genes	have	been	reported	to	cause	ONH.			Although	rare,	the	description	of	ONH	may	sometimes	be	confused	with	optic	atrophy23,24,	especially	when	serial	examinations	have	not	been	done,	and	the	examiner	cannot	appreciate	whether	there	has	been	a	progression	or	degeneration	over	time.	Optic	atrophy	is	a	condition	in	which	the	optic	nerve	tissues	had	developed	normally	and	either	are	damaged	and/or	degenerate	secondarily.				Although	ONH	can	occur	as	an	isolated	finding,	it	is	seen	much	more	frequently	as	part	of	a	syndrome.	ONH	is	usually	accompanied	by	other	anterior	segmental	defects	of	the	eye	(OMIM	607108)25,	structural	abnormalities	of	the	brain,	hypopituitarism	(OMIM	184429)26	,	developmental	delay/intellectual	disability15,27,	and	autism	spectrum	disorders28-30.	This	review	will	focus	on	the	genetic	mutations	that	are	currently	known	to	cause	ONH.	Herein,	we	will	define	ONH	broadly	as	any	optic	disc	that	shows	decreased	neuronal	area	and	small	optic	nerves,	congenitally.	The	reviews	of	the	more	narrowly	defined	septo-optic	dysplasia,	also	known	as	DeMorsier	syndrome,	can	be	found	elsewhere23,31,32.			To	date,	variants	in	genes	involved	in	transcription	regulation,	chromatin	remodeling,	α-dystroglycan	glycosylation,	cytoskeleton	and	scaffolding	protein,	RNA	splicing,	and	the	MAP	kinase	signaling	pathway,	have	been	associated	with	ONH.	In	the	first	part	of	the	review,	we	will	introduce	the	basic	functions	of	the	genes	
involved,	the	clinical	features	of	the	affected	individuals,	and	the	animal	models	used	to	study	the	respective	disorders.	In	the	second	part	of	the	review,	we	will	delineate	the	common	developmental	pathway	shared	by	some	of	the	key	transcription	factors	in	eye	development,	and	we	will	discuss	briefly	the	genes	associated	with	optic	nerve	atrophy.			
Transcription	factors	
	
HESX1	HESX1	homeobox	1	(HESX1)	encodes	a	homeobox	protein,	which	plays	an	important	role	in	normal	forebrain	development33	and	the	early	determination	and	differentiation	of	the	pituitary	gland34	in	murine	models.	Dattani	et	al.	reported	the	first	genetic	mutation	in	HESX1	(homozygous	p.R160C)	in	a	familial	case	(siblings	from	a	consanguineous	family)	of	Septo-Optic	Dysplasia	(SOD)35.	SOD	(MIM	182230)	is	defined	by	any	combination	of	i)	ONH,	ii)	pituitary	hypoplasia,	and	iii)	midline	neuro-radiological	abnormalities,	such	as	defects	in	the	corpus	callosum	and	septum	pellucidum.	Although	the	diagnosis	of	ONH	in	the	study	of	Dattani	et	al.	remained	controversial31,36,	subsequent	novel	heterozygous	HESX1	mutations	were	identified	in	patients	with	ONH	diagnosed	with	combined	pituitary	hormone	deficiency37	or	SOD38.	In	addition,	HESX1	constitutive	knockout	mice	(Hesx1-/-)	show	substantial	perinatal	and	postnatal	lethality	and	display	variable	anterior	CNS	defects	and	pituitary	dysplasia.	Anophthalmia,	microphthalmia,	defective	olfactory	development,	and	abnormalities	in	the	corpus	callosum,	hippocampal	commissures,	and	septum	pellucidum	were	described	in	Hesx1-/-	mice,	while	the	milder	phenotype	was	found	at	very	low	frequency	in	Hesx1+/-	mice	(1%)35.			
PAX6	Paired	box	gene	6	(PAX6)	encodes	a	transcription	factor	that	is	involved	in	eye	morphogenesis	during	embryonic	development39.	It	was	first	implicated	in	human	aniridia40,41	but	was	later	found	to	be	involved	in	other	eye	anomalies,	including	microphthalmia,	cataracts,	foveal	hypoplasia,	and	ONH	(OMIM	607108).	Although	ONH	is	not	common	in	individuals	with	PAX6	mutations,	Azuma	et	al.	reported	heterozygous	PAX6	mutations	(p.Q205X,	p.S292I,	and	p.M381V)	in	three	individuals	with	ONH,	one	of	whom	had	developmental	delay	and	intellectual	disability.	In	the	same	study,	they	also	identified	heterozygous	PAX6	mutations	(p.Q378R	and	p.T391A)	in	two	patients	with	optic	nerve	agenesis25.	Melanie	et	al.	summarized	ophthalmologic	evaluations	in	43	individuals	with	variable	anomalies	of	the	iris,	carrying	heterozygous	mutations	in	PAX6.	They	reported	that	nystagmus	and	foveal	hypoplasia	were	the	most	common	clinical	findings,	present	in	41	and	37	individuals,	respectively.	In	comparison,	ONH	was	found	in	10	individuals	in	this	cohort,	most	of	whom	carried	frameshift	mutations42.	Given	that	PAX6	is	also	a	master	regulator	of	neurogenesis43,	abnormalities	other	than	ocular	defects	have	also	been	reported,	including	developmental	delay25,	cognitive	impairment,	autism,	epilepsy,	and	structural	brain	abnormalities	of	white	matter,	mostly	the	corpus	callosum44-47.		
	To	date,	more	than	forty	Pax6	mutant	mouse	models	are	available	(Mouse	Genome	Informatics	(http://www.informatics.jax.org/)),	most	of	which	have	phenotypes	affecting	the	eyes/vision,	the	nervous	system,	craniofacial	development,	and/or	mortality.	One	of	the	first characterized	Pax6	mouse	models	is	the	Sey/Sey	(Small	eye)	mouse.	Sey/Sey	pups	are	born	without	both	eyes	and	nasal	cavities,	and	they	have	a	high	prevalence	of	perinatal	mortality	due	to	breathing	problems,	associated	with	the	absence	of	the	nose48.	Later	studies	showed	the	homozygous	knockout	animals	also	had	forebrain	defects	49.	Heterozygous	Sey/+	mice	have	milder	phenotypes.	These	mice	display	microphthalmia,	frequently	with	cataracts,	which	manifest	within	a	few	weeks	of	age,	retinal	abnormalities,	and	partial	or	complete	absence	of	the	iris50.		The	morphogenesis	of	the	optic	nerve	is	also	affected	in	Sey/+	mice.	The	cross	sectional	area	and	the	myelinated	fiber	counts	of	optic	nerves	are	decreased	significantly	in	heterozygous	mice,	although	the	effect	is	more	severe	in	male	mice	when	compared	to	female	heterozygous	mice;	the	mechanism	is	unclear51.			Similar	to	the	mouse	model,	a	Pax6	mutant	rat	model,	rSey2	(rat	Small	eye),	shows	that	homozygotes	(rSey/rSey)	do	not	develop	lens	and	nasal	placodes	and	are	perinatal	lethal,	while	heterozygotes	(rSey/+)	have	small	eyes52.	Later	in	life,	heterozygotes	are	shown	to	have	impaired	prepulse	inhibition,	altered	social	interaction,	and	low	performance	in	fear-conditioned	memory	tests.	Thus	the	authors	suggested	that	the	heterozygotes	likely	have	some	phenotypic	components	of	autism53.			The	pleiotropic	role	of	PAX6	during	development	can	be	appreciated	through	the	detailed	investigation	of	several	Pax6	mutant	mouse	models.	Pax6	consists	of	three	functional	domains:	the	paired	domain	(PD),	the	homeodomain	(HD),	and	the	transactivating	Proline-Serine-Threonine	domain	(PST).	Pax6	mutations	in	different	functional	domains	yield	different	phenotypes.	For	example,	Haubst	et	al.	compared	the	Pax64Neu	mutants	(HD	domain	mutation)	and	Pax6Aey18	mutants	(PD	domain	mutation),	and	found	out	that	while	the	former	had	only	subtle	effects	on	forebrain	development,	the	latter	had	severe	impairment	of	neurogenesis,	cell	proliferation,	and	patterning	in	the	developing	forebrain54.	The	molecular	consequences	of	
Pax6Leca2	and	Pax6Leca4	mutants,	which	carry	point	mutations	in	two	different	subdomains	within	the	PD	domain,	also	differed	greatly.	While	Pax6Leca2	mutants	increased	the	number	of	mitoses	in	the	developing	cerebral	cortex,	Pax6Leca4	mutants	showed	the	opposite.	Moreover,	neurogenesis	was	only	affected	in	Pax6Leca4	
,	but	not	Pax6Leca2	mutants55.	Acknowledging	that	the	total	number	of	unique	human	
PAX6	variants	reported	to	date	is	more	than	400	(Leiden	Open	Variation	Database	(http://lsdb.hgu.mrc.ac.uk/home.php?select_db=PAX6)),	and	recognizing	the	diversity	of	clinical	phenotypes	in	human	patients,	one	needs	to	consider	carefully	the	specific	mutation	to	provide	accurate	diagnosis,	counseling,	and	management.			
	
	
SOX2	SRY	(Sex	determining	region	Y)-box	2	(SOX2)	encodes	a	transcription	factor	that	is	essential	for	embryonic	development	of	multiple	organs,	including	the	brain	and	the	eyes56.	Heterozygous	SOX2	mutations	are	the	most	common	genetic	cause	for	bilateral	anophthalmia	and	severe	microphthalmia.	They	account	for	a	total	of	10-20%	of	all	patients	with	microphthalmia/anophthalmia57-59.	Among	235	individuals	diagnosed	with	congenital	hypothalamic-pituitary	disorders,	Kelberman	et	al.	reported	two	patients	(patient	7;	p.G130A	and	patient	8;	p.A191T)	with	bilateral	ONH	and	nystagmus26.	The	authors	discussed	the	possible	neutral	nature	of	these	two	SOX2	variants,	given	that	both	were	inherited	from	unaffected	fathers,	but	it	should	be	noted	that	incomplete	penetrance	for	SOX2	mutations	has	been	reported	elsewhere60.	In	the	same	study,	another	six	patients	with	microphthalmia/anophthalmia	were	found	to	carry	de	novo	SOX2	mutations,	and	four	out	of	five,	for	whom	MRI	data	was	available,	showed	either	hypoplastic	optic	nerves	or	complete	agenesis	of	the	optic	nerves.	Other	phenotypes	shared	by	these	patients	included	hippocampus	and	structural	anomalies	of	the	corpus	callosum.	Bakrania	et	al.	reported	a	female	patient	(case	2;	p.N63fs101X)	with	ONH	in	one	eye,	and	cataract,	atypical	coloboma,	and	esotropia	in	the	other	eye.	Other	extraocular	abnormalities	included	a	thin	corpus	callosum.	Ragge	et	al.	reported	two	patients	(case	6;	L314fs436X	and	case	7;	G23fs85X)	with	similar	phenotypes:	bilateral	anophthalmia,	attenuated	optic	nerves	without	visible	chiasm,	global	developmental	delay,	and	malformation	of	the	hippocampus61.	Jayakody	et	al.	reported	a	patient	(patient	1;	p.L97P),	diagnosed	with	bilateral	microphthalmia,	left	sclerocornea,	and	aphakia.	MRI	data	showed	right	microphthalmos	with	a	prosthesis	in	situ,	a	colobomatous	left	globe,	and	small	optic	nerves	and	chiasm62.			Homozygous	knockout	of	Sox2	causes	embryonal	lethality	in	mice,	with	the	products	of	conception	dying	shortly	after	implantation.	Heterozygous	knockout	mice	appear	normal,	except	for	a	noticeable	reduction	in	male	fertility63.	Although	heterozygous	knockout	mice	do	not	seem	to	recapitulate	the	human	eye	phenotypes,	Sox2	hypomorphic/null	compound	heterozygous	adult	mice	(expressing	40%	of	Sox2	compared	to	wild	type)	show	hypoplasia	of	optic	nerves	and	chiasmata,	with	eye	phenotypes	ranging	from	mild	bilateral	microphthalmia	to	severe	anophthalmia56,	much	like	heterozygous	patients.	The	authors	argued	that	the	striking	similarity	between	heterozygous	patients	and	compound	heterozygous	mouse	models	could	be	explained	by	species	differences;	alternatively,	it	has	been	suggested	that	humans	with	SOX2-related	eye	phenotypes	may	indeed	be	compound	heterozygotes,	carrying	a	null	allele	and	a	hypomorphic	allele	that	brings	the	total	functional	level	of	SOX2	down	to	a	range	that	results	in	phenotypic	expression56.					
NR2F1	Nuclear	receptor	subfamily	2	group	F	member	1	(NR2F1)	encodes	a	conserved	orphan	nuclear	receptor,	which	plays	a	critical	role	in	cortical	patterning64,65,	axon	guidance66,	neurogenesis66,	and	eye	and	optic	nerve	development67,68.	We	and	others	identified	heterozygous	NR2F1	mutations	in	individuals	manifesting	global	developmental	delay/intellectual	disability	and	ONH/optic	atrophy	(Bosch-
Boonstra-Schaaf	Optic	Atrophy	syndrome,	BBSOAS,	OMIM	615722)69-71.	The	phenotypic	spectrum	of	BBSOAS	included	hypotonia,	seizures,	autism,	oromotor	dysfunction,	thinning	of	the	corpus	callosum,	and	hearing	defects72.	To	date,	pathogenic	NR2F1	variants	have	been	reported	as	missense,	translation	initiation	variants,	frameshifting	indels,	and	whole	gene	deletions.	The	missense	mutations	were	enriched	in	the	two	functional	domains	of	NR2F1:	the	DNA-binding	domain	(DBD)	and	the	ligand-binding	domain	(LBD).	Notably,	patients	with	missense	mutations	in	the	DBD	generally	had	more	severe	phenotypes	compared	to	those	carrying	a	heterozygous	whole	gene	deletion.	Given	that	NR2F1	binds	to	DNA	in	the	form	of	dimers73,	a	dominant	negative	effect	may	be	the	cause	for	this	phenomenon.	A	genotype-phenotype	correlation	was	proposed:	patients	with	severe	clinical	phenotypes	carry	NR2F1	variants	that	tend	to	have	almost	completely	blunted	transcriptional	activity,	as	assessed	by	in	vitro	luciferase	assay69.			Homozygous	knockout	Nr2f1-/-	mice	die	within	the	first	two	days	after	birth	due	to	starvation	and	dehydration.	Defects	in	the	formation	of	the	glossopharyngeal	nerve	in	Nr2f1-/-	pups	have	been	proposed	as	the	cause74,	and	this	observation	may	relate	to	the	oromotor	dysfunction	seen	in	BBSOAS	patients.	Abnormal	development	of	the	corpus	callosum	and	the	hippocampal	commissure	also	is	seen	in	embryonic	Nr2f1-/-	brains75.	Eye-specific	double	knockout	of	Nr2f1	and	Nr2f2,	a	paralog	of	Nr2f1,	leads	to	ocular	colobomata,	microphthalmia,	and	abnormal	optic	cups.	The	expression	of	several	regulatory	genes	critical	for	early	optic	vesicle	development,	such	as	Pax6	and	Otx2,	are	altered	in	double	knockout	mice,	resulting	in	abnormal	differentiation	of	the	progenitor	cells	at	the	optic	vesicle68.	Although	all	the	BBSOAS	patients	identified	so	far	carry	heterozygous	NR2F1	variants,	a	heterozygous	knockout	(Nr2f1+/-)	mouse	model	has	not	been	reported.		
OTX2	Orthodenticle	homeobox	2	(OTX2)	encodes	a	homeodomain-containing	transcription	factor	that	plays	an	important	role	in	forebrain	and	eye	development76,77.	Heterozygous	mutations	in	OTX2	are	responsible	for	2-8%	of	patients	with	microphthalmia/anophthalmia78,79,	which	makes	them	the	second	most	common	genetic	cause	of	microphthalmia/anophthalmia	(after	SOX2).	Using	a	candidate-gene	approach,	Ragge	et	al.	first	reported	eight	patients	with	OTX2	variants	from	333	patients	with	ocular	malformation	spectrum	defects.	All	eight	patients	identified	in	the	study	had	microphthalmia/anophthalmia.	The	optic	nerves	and	chiasm	were	absent	or	reduced	in	four	out	of	the	six	patients	who	had	MRI,	CT,	or	ultrasound	data	available	for	review80.	Later	studies	showed	that	35%	of	the	patients	with	OTX2	mutations	had	ONH,	while	other	eye	defects	such	as	coloboma	and	retinal	dystrophies	were	less	common79.	In	addition	to	ocular	abnormalities,	the	phenotypic	spectrum	of	OTX2	mutations	included	structural	and	functional	abnormalities	of	the	pituitary,	global	developmental	delay,	autism,	attention	deficit	disorder,	feeding	difficulties,	seizures,	microcephaly,	and	other	structural	brain	anomalies,	affecting	the	corpus	callosum	and	hippocampus79-81.	Incomplete	penetrance	and	variable	expressivity	have	been	reported	for	OTX2	mutations.	In	the	original	study,	three	out	of	eight	affected	individuals	inherited	their	mutations	from	
a	phenotypically	normal	parent,	including	frameshift	or	nonsense	mutations.	Variable	expressivity	has	been	documented	extensively,	including	individuals	sharing	the	same	variant,	even	among	siblings80.	Homozygous	knockout	mice	(Otx2-
/-)	are	embryonically	lethal	and	display	abnormal	development	of	the	forebrain,	midbrain,	and	rostral	hindbrain76.	Heterozygous	mice	show	variable	phenotypes,	including	anencephaly,	holoprosencephaly,	microphthalmia/anophthalmia,	micrognathia/agnathia,	and	short	nose82.		
VAX1	Ventral	anterior	homeobox	1	(VAX1)	encodes	a	homeobox	transcription	factor,	which	plays	an	important	role	in	the	forebrain	and	visual	system83,84.	Slavotinek	et	al.	identified	a	homozygous	missense	VAX1	variant	(p.R152S)	in	a	screen	of	70	individuals	with	microphthalmia/anophthalmia.	The	affected	male	patient	was	born	to	phenotypically	normal,	consanguineous	parents,	who	were	confirmed	as	heterozygous	carriers	of	the	variant.	In	addition	to	microphthalmia,	other	clinical	features	included	ONH,	global	developmental	delay,	hippocampal	malformations,	agenesis	of	the	pineal	gland	and	corpus	callosum,	and	cleft	lip/palate85.	Homozygous	knockout	Vax1-/-	mice	are	perinatally	lethal,	and	the	observed	phenotypes	bear	remarkable	similarity	to	the	human	patient:	optic	nerve	dysgenesis,	coloboma,	and	abnormalities	in	brain	structures	(corpus	callosum,	hippocampus,	and	anterior	commissure)83,84.	It	should	be	noted	that	heterozygous	knockout	Vax1+/-	mice	appear	normal,	except	for	subfertility86.		
ATOH7	Atonal	homolog	BHLH	transcription	factor	7	(ATOH7)	encodes	a	basic	helix-loop-helix	transcription	factor,	which	is	critical	for	retinal	ganglion	cell	and	optic	nerve	formation87.	Khan	et	al.	reported	two	homozygous	ATOH7	variants	(one	missense	and	the	other	as	frameshift	variant)	in	two	consanguineous	families	with	isolated	microphthalmia.	Two	affected	siblings	from	the	family	with	frameshift	mutations	also	displayed	ONH,	corneal	opacity,	and	retinal	detachment.	Co-segregation	of	this	mutation	with	the	clinical	phenotype	was	confirmed	in	the	family88.	The	finding	was	supported	by	two	genome-wide	association	studies,	which	identified	SNP	(rs3858145,	p=3.4	x	10-10)	and	SNP	(rs1900004,	p=2.67	x	10-33)	within	20	kb	and	10	kb	of	ATOH7,	respectively89,90.	However,	pathogenic	ATOH7	variants	were	not	discovered	in	an	investigation	of	34	patients	with	ONH91	and	76	other	patients	with	microphthalmia/anophthalmia/coloboma92.	Homozygous	knockout	Atoh7-/-	mice	are	viable,	fertile,	and	appear	normal	externally.	Although	they	tend	to	have	normal	sized	eyes,	there	is	a	80-95%	reduction	in	the	number	of	retinal	ganglion	cells,	with	very	thin	or	absent	optic	nerves87,93.			
Chromatin	remodeling		
KANSL1	(17q21.31	microdeletion)	KAT8	regulatory	NSL	complex	subunit	1	(KANSL1)	encodes	a	nuclear	protein	that	is	a	key	component	of	a	histone	acetyltransferase	(HAT)	complex94,95.	KANSL1	is	one	of	
the	five	known	protein-coding	genes	in	the	17q21.31	microdeletion	syndrome	locus	(MIM	610443).	It	was	later	found	that	haploinsufficiency	of	KANSL1	was	sufficient	to	cause	the	phenotypes	of	17q21.31	microdeletion	syndrome,	also	known	as	Koolen-de	Vries	syndrome	(KdVS)96.	KdVS	is	a	multisystem	disorder,	characterized	by	developmental	delay/intellectual	disability,	hypotonia,	and	characteristic	facial	dysmorphism.	Additional	features	include	overly	social	and	friendly	behavior,	epilepsy,	congenital	heart	defects,	urogenital	malformations,	musculoskeletal	anomalies,	and	ectodermal	anomalies.	Zollino	et	al.	reported	a	deletion	patient	(patient	28)	with	hypoplastic	ocular	globe,	unilateral	ONH,	strabismus,	hearing	impairment,	and	craniosynostosis.	Koolen	et	al.	reported	another	deletion	patient	(case	32)	with	ONH,	hypermetropia,	strabismus,	esotropia,	and	corpus	callosum	abnormality97.	The	third	deletion	patient	reported	manifested	cataracts,	optic	atrophy,	hearing	impairment,	and	a	small	hippocampus98.		Currently	no	mouse	model	for	Kansl1	deletion	exists.	Knockout	of	wah	(KANSL1	ortholog	in	Drosophila)	is	embryonal	lethal	in	flies.	Tissue-specific	knockdown	of	wah	in	muscles	and	mushroom	bodies	(the	learning	and	memory	centers	in	Drosophila	brains)	leads	to	neuromuscular-junction	defects	and	decreased	learning	ability96,99.	The	function	of	
wah	in	eye	development	is	unknown	currently.		
α-dystroglycan	glycosylation	
	
B3GALNT2	Beta-1,3-N-Acetylgalactosaminyltransferase	2	(B3GALNT2)	encodes	a	glycosyltransferase	that	helps	to	synthesize	α-dystroglycan,	which	is	an	integral	component	of	the	dystrophin	glycoprotein	complex.	Defects	in	glycosylation	reduce	the	binding	ability	of	α-dystroglycan	to	extracellular	matrix	ligands,	causing	a	dystroglycanopathy.	Stevens	et	al.	reported	seven	individuals	with	congenital	muscular	dystrophy-dystroglycanopathy,	and	a	phenotype	defined	as	“brain	and	eye	anomalies	type	A11”	(MDDGA11,	MIM	615181).	These	individuals	carried	either	homozygous	or	compound	heterozygous	mutations	in	B3GALNT2.	Two	of	the	affected	individuals	had	ONH.	Currently,	there	is	no	murine	model	for	B3galnt2	loss-of-function	studies;	however,	knockdown	of	b3galnt2	in	zebrafish	showed	retinal	degeneration,	impaired	motility,	and	brain	abnormalities100		
ISPD	Isoprenoid	synthase	domain-containing	protein	(ISPD)	encodes	a	protein	that	is	required	for	proper	α-dystroglycan	modification.	Similar	to	B3GALNT2,	ISPD	mutations	were	identified	in	patients	diagnosed	with	congenital	muscular	dystrophy-	dystroglycanopathy	with	brain	and	eye	anomalies,	in	this	case	type	A7	(MDDGA7,	MIM	614643).	Willer	et	al.	reported	seven	individuals,	including	a	pair	of	siblings,	carrying	homozygous	or	compound	heterozygous	mutations	in	ISPD.	Two	of	the	seven	patients	had	ONH.	One	of	the	affected	siblings	was	diagnosed	with	bilateral	ONH,	and	the	other	had	bilateral	microphthalmia	(status	of	optic	nerves	not	mentioned	in	the	study)101.		Roscioli	et	al.	identified	two	individuals	with	MDDGA7,	one	with	a	homozygous	and	the	other	with	compound	heterozygous	
mutations	in	ISPD.	However,	instead	of	being	described	with	ONH,	they	were	diagnosed	with	optic	atrophy102.	In	addition	to	eye	abnormalities,	the	four	individuals	also	shared	brain	malformations,	including	hydrocephalus,	cerebellar	hypoplasia,	and	cobblestone	lissencephaly.	In	a	forward	genetic	screen	for	axon	guidance	defects,	it	was	found	that	a	homozygous	loss-of-function	mutation	in	a	mouse	model	IspdL79*/L79*	(leucine	to	premature	stop	codon)	leads	to	neonatal	lethality,	abnormal	axon	guidance	in	the	hindbrain,	and	abnormal	fasciculation	of	the	funiculus	of	the	spinal	cord.	However,	eye-related	phenotypes	were	not	reported	in	that	mouse	study103.		
Cytoskeleton	and	Scaffolding	protein	
	
TUBA8	Tubulin	alpha	8	(TUBA8)	encodes	a	member	of	the	α-tubulin	protein	family.	α-and	β–tubulins	heterodimerize	and	then	assemble	to	form	microtubules.	Abdollahi	et	al.	reported	homozygous	indel	in	an	intron	of	TUBA8	in	three	affected	members	of	a	consanguineous	Pakistani	family.	The	same	homozygous	deletion	was	found	in	an	affected	child	from	a	second	Pakistani	family.	The	14	bp	deletion	lies	11	bp	upstream	of	the	exon	2	splice	junction.	The	deletion	was	predicted	to	interfere	with	correct	splicing,	which	was	verified	by	the	reverse	transcription	polymerase	chain	reaction	of	lymphoblastoid	cell	line	RNA	from	the	patient.	All	four	affected	children	have	ONH	with	polymicrogyria.	Other	shared	clinical	phenotypes	include	seizures,	thin	or	absent	corpus	callosum,	and	brainstem	abnormalities104.	Surprisingly,	follow-up	studies	showed	that	the	expression	of	Tuba8	was	relatively	low	in	developing	mouse	and	human	brains,	even	though	the	clinical	phenotypes	mainly	present	as	brain	malformations105.	Currently,	no	mouse	model	exists	for	Tuba8	mutations.	
	
CASK	Calcium/calmodulin-dependent	serine	protein	kinase	(CASK)	encodes	a	member	of	the	membrane-associated	guanylate	kinase	(MAGUK)	protein	family,	which	consists	of	scaffolding	proteins	associated	with	intercellular	junctions106.	Heterozygous	or	hemizygous	mutations	in	the	X-linked	CASK	gene	in	patients	lead	to	microcephaly	with	pontine	and	cerebellar	hypoplasia	(MICPCH,	MIM	300749)107.	The	phenotypic	spectrum	of	CASK	mutations	includes	autistic	traits,	developmental	delay/intellectual	disability,	axial	hypotonia	and/or	peripheral	hypertonia,	movement	and	behavioral	disorders,	and	seizures.	Although	optic	nerve	hypoplasia/optic	atrophy	is	not	fully	expressed	in	MICPCH	patients,	it	has	been	reported	in	multiple	studies108-111.	Other	ophthalmological	abnormalities	include	hyperopia,	strabismus,	astigmatism,	and	nystagmus.	Constitutive	knockout	mice	(Cask-/y)	and	(Cask-/-)	die	within	the	first	day	after	birth106,	but	deletion	of	a	single	
Cask	allele	(Cask+/-)	in	female	mice	has	been	found	to	recapitulate	many	human	phenotypes,	including	microcephaly,	hypotonia,	ataxia,	and	ONH	without	microphthalmia	or	malformation	of	the	brain	midline112.	The	study	suggested	that	Cask	regulates	oxidative	metabolism	in	the	brain,	and	the	rate	of	glucose	oxidation	
was	reduced	by	20%	in	the	brain	of	Cask+/-	mice	compared	with	wild	type	littermates112.			
RNA	splicing	
	
PUF60	Poly(U)	binding	splicing	factor	60	(PUF60)	encodes	a	ribonucleoprotein-binding	protein,	which	is	involved	in	pre-mRNA	splicing	and	transcriptional	regulation.	Dauber	et	al.	identified	the	first	patient	with	a	de	novo	heterozygous	variant,	p.H169Y	in	PUF60113.	El	Chehadeh	et	al.	reported	another	five	patients	with	de	novo	heterozygous	variants	in	PUF60114.	All	six	patients	identified	to	date	manifest	the	same	facial	gestalt	as	seen	in	individuals	with	8q24.3	microdeletion	syndrome,	also	known	as	Verheij	syndrome	(MIM	615583).	Other	shared	clinical	features	include	bilateral	ONH	(2/6),	developmental	delay	(6/6),	cardiac	defects	(5/6),	short	stature	(5/6),	joint	laxity	and/or	dislocation	(5/6),	vertebral	anomalies	(3/6),	and	feeding	difficulties	(3/6).	Currently,	there	is	no	mouse	model	for	Puf60	mutations.		
MAPK	signaling	pathway		
BRAF	B-Raf	proto-oncogene	(BRAF)	encodes	a	serine/threonine-protein	kinase	that	plays	a	role	in	regulating	the	MAP	kinase	signaling	pathway.	Mutations	in	BRAF	are	one	of	the	causes	of	cardio-facio-cutaneous	(CFC)	syndrome	(MIM	115150).	Armour	et	al.	compiled	clinical	data	on	38	individuals	with	CFC,	which	was	characterized	clinically	by	heart	defects,	distinctive	facial	features,	and	skin	abnormalities.	The	analysis	showed	that	32/38	individuals	carried	autosomal	dominant	variants	in	BRAF.	The	remaining	6	individuals	carried	either	MEK1	or	MEK2	variants.	Among	the	patients	with	BRAF	mutations,	optic	nerve	hypoplasia/dysplasia	was	diagnosed	in	9	out	of	the	20	individuals	who	had	provided	ophthalmological	assessments	for	review.	Meanwhile,	2	out	of	6	individuals	carrying	MEK1	or	MEK2	variants	had	such	diagnoses115.	Note	that	both	MEK1	and	MEK2,	like	BRAF,	are	also	integral	parts	of	the	MAP	kinase	pathway.	As	a	result,	mutations	in	any	of	these	genes	lead	to	similar	phenotypes	in	CFC.	Although	the	signs	of	CFC	overlap	substantially	with	Noonan	syndrome,	it	was	estimated	that	only	2%	(3/139)	of	Noonan	syndrome	patients	had	ONH116.	Given	that	most	BRAF	mutations	found	in	CFC	patients	were	predicted	to	result	in	hyperactivation	of	BRAF,	multiple	corresponding	mouse	models	have	been	generated.	Braf+/V600E	and	Braf+/L597V	mouse	models,	both	carrying	an	allele	expressing	constitutively	active	Braf	protein,	recapitulate	certain	patient	phenotypes,	including	small	body	size,	facial	dysmorphism,	cardiomegaly,	and	eye	abnormalities	(cataracts)117,118.				
	
	
	
	
Others	
	
ALDH1A3	Aldehyde	dehydrogenase	1	family	member	A3	(ALDH1A3)	encodes	an	aldehyde	dehydrogenase	enzyme	that	uses	retinal	(retinaldehyde)	as	a	substrate	to	synthesize	retinoic	acid,	which	plays	a	critical	role	in	eye	development119.	Fares-Taie	et	al.	identified	two	homozygous	missense	mutations	(p.R89C	and	p.A493P)	and	one	homozygous	splice-site	mutation	in	four	individuals	from	three	consanguineous	families.	These	mutations	segregated	with	microphthalmia/anophthalmia	along	with	occasional	orbital	cystic,	neurological,	and	cardiac	anomalies	in	the	family.	Available	MRI	data	from	two	individuals	showed	hypoplastic	optic	nerves120.	Yahyavi	et	al.	identified	a	homozygous	nonsense	mutation,	p.L389*,	which	they	predicted	to	cause	nonsense-mediated	decay,	in	a	patient	with	microphthalmia/anophthalmia	and	hypoplasia	of	the	optic	nerve	and	optic	chiasm121.	Homozygous	knockout	Aldh1a3-/-	mice	are	lethal	perinatally	and	show	defects	in	the	invagination	of	the	ventral	optic	cup,	closure	of	the	choroid	fissures,	and	abnormal	axonal	projections	of	retinal	cells	into	the	brain119,122,123.	Interestingly,	Aldh1a3	is	also	critical	for	the	development	of	nasal	structures,	and	null	mice	die	of	respiratory	distress	at	birth,	resulting	from	choanal	atresia	(blockage	of	nasal	passage).	However,	all	the	human	patients	reported	to	date	do	not	display	these	nasal	or	choanal	abnormalities,	suggesting	residual	protein	function	of	the	pathogenic	alleles,	or	species-dependent	differences	in	mice	vs.	humans.		
DDHD2	DDHD	domain-containing	protein	2	(DDHD2)	encodes	a	phospholipase	enzyme	and	is	a	major	brain	triglyceride	hydrolase.	Schuurs-Hoeijmakers	et	al.	reported	five	individuals	diagnosed	with	complex	hereditary	spastic	paraplegia	(SPG54,	MIM	615033)	carrying	biallelic	mutations	in	DDHD2.	Three	out	of	five	individuals	had	ONH.	Other	shared	features	included	developmental	delay/intellectual	disability,	hypotonia,	strabismus,	and	thin	corpus	callosum124.	Ddhd2	constitutive	knockout	mice	(Ddhd2−/−)	exhibit	defects	in	movement	and	cognitive	function,	and	show	selective	elevation	in	triacylglycerols	through	the	CNS.	However,	the	visual	ability	in	these	mice	is	not	different	substantially	from	wildtype	controls	in	the	optomotor	test125.		
Discussion	
	
Molecular	network	of	transcription	factors	in	eye	development	Eye	morphogenesis	in	vertebrates	is	an	intricate	multi-step	process,	including	the	formation	of	the	eye	pit,	optic	vesicle,	optic	cup,	lens,	and	neurogenesis	in	the	neural	retina	(Figure	1).	Many	key	transcription	factors	participate	in	these	sequential	events	to	ensure	the	proper	formation	and	maturation	of	the	eye126,127.	While	most	knowledge	described	here	is	derived	from	murine	studies,	a	high	level	of	conservation	exists	for	the	sequence	and	function	of	these	key	transcription	factors	
in	eye	development	between	human	and	murine	models,	so	the	described	processes	carry	significance	in	humans	as	well.	In	mice,	the	evagination	of	optic	pits	leads	to	the	formation	of	the	early	optic	vesicle	at	E9.5.	Then,	the	invagination	of	optic	vesicle	at	E10.5	results	in	the	formation	of	a	dual-layered	optic	cup,	which	consists	of	three	main	domains:	the	neural	retina	(NR),	retinal	pigmented	epithelium	(RPE),	and	optic	stalk	(OS).	The	OS	later	becomes	the	optic	nerve	when	the	axons	of	the	retinal	ganglion	cells	fill	the	cavity	of	the	stalk	and	complete	the	closure	of	the	choroid	fissure	(Figure	1).			 The	boundary	between	optic	stalk	and	neural	retina	is	established	at	the	optic	disc,	which	serves	an	entrance	for	the	blood	vessels	to	the	eye	and	as	an	exit	for	the	axons	of	retinal	ganglion	cells	from	the	eye128.	Pax6,	an	NR	marker,	and	Pax2,	a	ventral	OS	marker,	antagonize	each	other	to	establish	the	sharp	boundary	(Figure	
1)129.	Reciprocal	expansion	of	Pax2	and	Pax6	gene	expressions	is	seen	in	the	corresponding	loss-of-function	mutant	mice.	Disruption	of	this	boundary	causes	defects	in	the	optic	nerve,	optic	stalk,	retina,	lens,	and	optic	fissure	closure130,131.	Vax1	and	Vax2	are	also	involved	in	the	boundary	formation,	by	inhibiting	Pax6	expression,	given	that	the	expression	of	Pax6	and	Pax2	is	rapidly	acquired	and	lost	from	the	optic	stalk	in	Vax1	and	Vax2	double	knockouts	at	E10132.			 Another	example	of	boundary	formation	defects	is	reported	in	Nr2f1	and	
Nr2f2	double	knock	mice.	Increased	expression	of	Pax6	in	NR	and	decreased	expression	of	Pax2	in	ventral	NR,	accompanied	by	reduced	expression	of	Pax2/Vax1	in	the	OS,	shifts	the	NR-vOS	boundary	proximally,	eventually	leading	to	abnormal	differentiation	of	the	optic	stalk68.	These	data	suggested	that	Nr2f1	and	Nr2f2	are	the	key	regulators	that	balance	the	expression	of	Pax6	and	Pax2	during	the	early	development	of	the	optic	cup.	However,	the	eye	phenotypes	in	the	individuals	with	heterozygous	PAX6	mutations	are	generally	more	severe	than	those	with	heterozygous	NR2F1	mutations.	This	could	be	explained	by	the	functional	redundancy	between	NR2F1	and	NR2F2,	given	that	eye-specific	double	knockout	of	
Nr2f1	and	Nr2f2	in	mice	leads	to	major	eye	abnormalities	but	does	not	do	so	in	eye-specific	single	knockout	of	Nr2f168.			 Two	transcription	factors	synergistically	regulating	lens	development	are	Pax6	and	Sox2,	again	indicating	the	intricate	interaction	between	transcription	factors	during	eye	development133,134.	Pax6	and	Sox2	form	a	co-DNA-binding	complex,	which	activates	cooperatively	the	lens-specific	enhancer	elements	DC5	in	order	to	differentiate	embryonic	ectoderm	into	lens	ectoderm.	In	contrast	to	the	synergistic	relationship,	the	same	two	transcription	factors	antagonize	each	other	in	the	developing	optic	cup,	to	specify	the	multipotent	optic	cup	progenitors	toward	a	neurogenic	fate	(Sox2)	or	a	non-neurogenic	fate	(Pax6)135.	This	suggests	that	the	interplay	between	transcription	factors	may	be	highly	cell	type-specific	and	developmental	stage-specific	during	eye	development.			 Adding	to	the	complexity	of	eye	development	is	the	fact	that	the	aforementioned	transcription	factors	are	also	involved	in	the	morphogenesis	of	the	forebrain	and	other	brain	regions,	such	as	the	midline	brain,	hypothalamus,	and	pituitary	gland.	This	involvement	may	explain	why	ONH	is	more	commonly	a	part	of	a	syndrome	involving	other	structural	brain	anomalies,	rather	than	an	isolated	finding.	Similarly,	most	mutant	mouse	models	manifest	more	extensive	systemic	
defects,	in	addition	to	isolated	ONH.	To	date,	multiple	genes	are	implicated	in	ONH;	however,	most	of	them	are	associated	with	other	eye	anomalies	and/or	brain	structural	defects.	Nevertheless,	the	possibility	that	one	single	gene	mutation	leads	to	isolated	ONH	should	not	be	discounted.		
Mitochondrial	optic	neuropathy	In	contrast	to	ONH,	the	genetic	causes	of	optic	atrophy	are	mostly	mitochondria-related.	Leber	hereditary	optic	neuropathy	(LHON)	and	dominant	optic	atrophy	(DOA)	are	the	two	most	common	inherited	optic	atrophy	disorders136.	Mutations	in	primary	mitochondrial	DNA	(mtDNA)	affect	the	respiratory	chain	complexes	in	LHON137.	Mutations	in	OPA1,	which	encodes	an	inner	mitochondrial	membrane	protein	important	for	oxidative	phosphorylation	and	mtDNA	maintenance,	account	for	three-quarters	of	all	DOA	patients138,139.	Other	genes	implicated	in	optic	atrophy	include	FXN140,	TIMM8A141,	SPG7142,	MFN2143,	DNM1L144,	OPA3145,	SDHA146,	CISD2147,	and	SLC25A46148,149.	All	these	genes	encode	mitochondrial	proteins	and	presumably	are	involved	in	energy	metabolism,	although	genes	not	directly	related	to	mitochondria	exist,	such	as	KIF1A150,	KLC2151,	and	ATP1A3152.	Tissues	with	high-energy	demand,	such	as	those	found	in	the	nervous	system	and	skeletal	muscles	are	more	vulnerable	to	mitochondrial	dysfunction.	This	could	explain	why	patients	with	these	mutations	typically	manifest	optic	atrophy	and/or	myopathy	at	its	onset.	Nevertheless,	the	association	of	ONH	with	mitochondrial	cytopathies	has	been	reported	and	will	require	further	investigation153.					
Conclusion	With	ONH	being	the	second	most	common	cause	of	congenital	visual	impairment154,	the	investigation	of	the	causes	and	risk	factors	of	ONH	is	of	great	importance.	Although	previous	studies	had	mostly	attributed	ONH	to	the	prenatal	environment,	the	identification	of	an	increasing	number	of	genetic	causes	of	ONH	suggests	multiple	etiological	mechanisms,	including	gene-environment	interactions,	as	well	as	monogenic	causes	with	high	penetrance.	The	consideration	of	gene-environment	interactions	and	potential	genetic	modifiers	is	based,	in	part,	on	the	presence	of	variable	expressivity	of	related	phenotypes	among	individuals	carrying	the	same	genetic	variants.			Eye	morphogenesis	in	mammalian	species	is	an	intricate	process.	Many	key	transcription	factors	relevant	for	eye	development	also	play	roles	in	the	morphogenesis	of	forebrain.	This	interplay	causes	more	complex	clinical	phenotypes,	many	of	which	involve	cognitive	deficits	and	behavioral	alterations.	With	the	advancement	and	clinical	availability	of	genome-wide	sequencing	technology,	we	anticipate	that	more	genes	will	be	implicated	in	the	etiology	of	ONH.	In	some	cases,	the	modes	of	inheritance	may	go	well	beyond	Mendelian	genetics,	e.g.,	digenic	or	oligogenic	inheritance.	These	steps	will	lead	to	an	increased	molecular	diagnostic	rate	for	individuals	with	ONH	per	se.	Additional	research	will	investigate	whether	the	functional	consequences	associated	with	the	respective	disorders	are	all	due	to	structural	deficits	from	altered	neurodevelopment,	or	whether	some	function(s)	could	be	regained,	with	therapeutic	intervention,	even	started	later	in	life.		
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Figure	1.	Eye	development	and	key	transcription	factors.	In	early	eye	development,	the	evagination	of	optic	pits	leads	to	the	formation	of	the	early	optic	vesicle.	The	surface	ectoderm	and	the	underlying	neuroepithelium	invaginate	to	form	the	lens	vesicle	and	bilayered	optic	cup,	respectively.	The	outer	layer	of	the	optic	cup	gives	rise	to	the	retinal	pigment	epithelium,	while	the	inner	layer	gives	rise	to	the	neural	retina.	The	optic	stalk	later	becomes	the	optic	nerve	when	the	axons	of	the	retinal	ganglion	cells	fill	the	cavity	of	the	stalk	and	complete	the	closure	of	the	choroid	fissure.	Many	key	transcription	factors,	mutations	of	which	cause	ONH,	participate	in	the	proper	development	of	the	optic	stalk/optic	nerve.	RPE,	retinal	pigment	epithelium;	RGC,	retinal	ganglion	cell.	
